Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3335450
Max Phase: Preclinical
Molecular Formula: C89H145N23O21S3
Molecular Weight: 1969.48
Molecule Type: Protein
Associated Items:
ID: ALA3335450
Max Phase: Preclinical
Molecular Formula: C89H145N23O21S3
Molecular Weight: 1969.48
Molecule Type: Protein
Associated Items:
Canonical SMILES: CSCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(C)=O)C(C)C)C(=O)N[C@H]1CCSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(=O)O)C(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC1=O
Standard InChI: InChI=1S/C89H145N23O21S3/c1-49(2)44-61-78(123)100-57(26-17-37-95-89(93)94)74(119)99-56(24-13-15-35-90)75(120)106-63(45-50(3)4)86(131)109-38-18-27-66(109)82(127)96-52(7)73(118)107-64(47-113)80(125)105-62(46-54-22-11-10-12-23-54)79(124)108-65(48-136-135-43-34-59(77(122)104-61)101-76(121)58(33-42-134-9)102-84(129)68-29-20-40-111(68)88(133)71(51(5)6)97-53(8)114)81(126)103-60(25-14-16-36-91)85(130)112-41-21-30-69(112)87(132)110-39-19-28-67(110)83(128)98-55(72(92)117)31-32-70(115)116/h10-12,22-23,49-52,55-69,71,113H,13-21,24-48,90-91H2,1-9H3,(H2,92,117)(H,96,127)(H,97,114)(H,98,128)(H,99,119)(H,100,123)(H,101,121)(H,102,129)(H,103,126)(H,104,122)(H,105,125)(H,106,120)(H,107,118)(H,108,124)(H,115,116)(H4,93,94,95)/t52-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,71-/m0/s1
Standard InChI Key: LRHGOSSFDNWQQB-OUJIWQJGSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1969.48 | Molecular Weight (Monoisotopic): 1968.0148 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Zhang Z, Lin Z, Zhou Z, Shen HC, Yan SF, Mayweg AV, Xu Z, Qin N, Wong JC, Zhang Z, Rong Y, Fry DC, Hu T.. (2014) Structure-Based Design and Synthesis of Potent Cyclic Peptides Inhibiting the YAP-TEAD Protein-Protein Interaction., 5 (9): [PMID:25221655] [10.1021/ml500160m] |
Source(1):